Metropolis Healthcare Limited — PPTs, 04-02-2025: Investor Presentation

**Financial Highlights**: Metropolis Healthcare reported Q3FY25 revenue of INR 323 Cr, reflecting a 10.9% year-on-year growth. EBITDA was INR 72 Cr with a margin of 22.2%, while PAT increased to INR 31 Cr, marking a 15.3% rise. For the nine-month period, revenue reached INR 986 Cr, up 12.5% year-on-year, with EBITDA growing faster at 17.8% to INR 241 Cr, highlighting strong operational leverage.

**Strategic Initiatives and Growth Drivers**: The company is focused on expanding its core diagnostics capabilities and enhancing service offerings through the Metropolis 3.0 strategy, which prioritizes digital transformation, network expansion, and specialized testing.

**Business Developments**: Metropolis is set to acquire Core Diagnostics, a leading oncology lab, for an equity value of INR 246.8 Cr, enhancing its market presence. This acquisition is expected to be EPS accretive from FY26.

**Market Position and Competitive Advantage**: Metropolis maintains a robust market position, with a diversified revenue base across B2C and B2B segments. B2C revenue grew by 15% YoY in Q3FY25, indicating strong trust among patients and professionals alike.

**Investor Implications**: The company's ongoing investments, strategic acquisitions, and focus on high-margin services offer a positive outlook for growth and profitability. Retail investors should watch for the impacts of the Core Diagnostics acquisition and continued execution of growth strategies in the coming quarters.